
==== Front
Crit Care
Critical Care
1364-8535
1466-609X
BioMed Central London

5070
10.1186/s13054-024-05070-3
Matters Arising
Cytomegalovirus end-organ disease in immunocompromised critically ill patients: key concerns demanding attention
Zhang Zhihui
Sun Junlu
Liu Xuesong
Zhang Rong
Li Yimin dryiminli@vip.163.com

Liu Xiaoqing lxq1118@126.com

grid.410737.6 0000 0000 8653 1072 Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong People’s Republic of China
10 9 2024
10 9 2024
2024
28 29815 8 2024
17 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Science and Technology Program of GuangzhouSL2023A04J00179, 2024A04J3312 Zhang Zhihui National Natural Science Foundation of China82070084 Liu Xiaoqing Guangzhou Clinical Specialty Program2023C-TS01 Liu Xiaoqing issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcWe delved into the clinical research conducted by Sara Fernández et al. [1] with great interest. This study is a multicenter, international research initiative spanning over a decade, primarily focusing on cytomegalovirus end-organ disease (CMV-EOD) among immunosuppressed patients with critical illness. The study revealed distinctive clinical features, risk factors, and adverse clinical outcomes in immunocompromised critically ill patients with CMV-EOD, marking it as a seminal work in the field. However, there is scope for enhancing the comprehensiveness of this study with further refinements.

First, within the specific population of immunocompromised critically ill patients, certain subjects (such as those with sepsis, trauma, and other prolonged illnesses) have been overlooked and excluded. Sepsis, a significant global health concern characterized by severe response to infection that causes organ failure, leads to over 5.3 million deaths yearly, with a mortality rate of around 30% [2–4]. Sepsis is currently understood to induce an imbalance in the immune system (innate and adaptive), leading to phenomenon known as "immune paralysis" [5–7]. The early stages (characterized by overwhelming inflammation) and the later stages (characterized by refractory inflammation, immunosuppression, and risk of secondary infections) of sepsis are both conducive to CMV reactivation [5–8]. The incidence of CMV reactivation in septic patients seems to be similar to other common immunosuppressed patients [8]. Our team's research indicates the incidence of CMV reactivation in critically ill patients with concurrent sepsis increases by at least 30%, and sepsis is an independent risk factor for CMV reactivation [9, 10]. This aligns with other mainstream research findings, where the underlying mechanism is associated with sepsis-induced immunosuppression, promoting CMV replication [11]. Therefore, definition of immunosuppressed population in CMV-EOD research should be broadened, and more effective immune function assessment indicators are required to clearly define "immunocompromised", moving beyond reliance on clinical disease types for judgment.

Second, assessing the impact of CMV load levels on clinical characteristics and outcomes in CMV-EOD population is essential. Additionally, it is necessary to evaluate CMV seropositivity, both qualitatively and quantitatively, as recent studies indicate a close relationship between CMV seropositivity and poor prognosis [12]. A combined assessment of CMV load and IgG in blood may enable earlier identification of high-risk patients, allowing for antiviral treatment to improve adverse outcomes. Third, the antiviral medications used for the subjects with CMV-EOD in this study may exert a negative influence on prognosis, primarily due to bone marrow suppression leading to a decrease in immune cell levels [13]. The use of the latest anti-CMV drugs Letermovir and Maribavir may mitigate these adverse effects [14]. Finally, CMV should be recognized as a systemic infectious virus, not confined to a specific organ but widely infecting various cell types, including epithelial, endothelial, fibroblast cells, and so on [15]. Notably, CMV resides in the body as a latent infection and can reactivate under immunosuppressed conditions, leading to multi-system organ damage, particularly affecting the respiratory and digestive systems in patients with CMV-EOD. However, whether CMV is a pathogen or a bystander remains a significant and unresolved question. The prevailing view is that CMV reflects immune status and has pathogenicity, especially as reactivation is more likely with lower immune function, and the pathogenicity increases with viral load. In addition, the impact of other co-infections on prognosis needs to be clarified.

In conclusion, the study by Sara Fernández et al. describes the clinical characteristics and outcomes of immunocompromised critically ill patients with CMV-EOD, thus contributing positively to the advancement of the field. A nuanced investigation into the aforementioned matters is essential to fully elucidate the intricate interplay between CMV-EOD and poor prognosis in immunocompromised critically ill patients. Further research should delve deeper into these complexities to enhance our understanding and potentially inform more effective therapeutic strategies.

Abbreviations

CMV Cytomegalovirus

CMV-EOD Cytomegalovirus End-Organ Disease

Acknowledgements

Not applicable.

Author contributions

ZHZ wrote the manuscript; ZHZ, JLS, XSL, and RZ revised the manuscript; XQL and YML reviewed the manuscript. XQL and YML contributed equally to the study. All authors read and approved the final manuscript.

Funding

The study was funded by the National Natural Science Foundation of China (No. 82070084), Science and Technology Program of Guangzhou (Nos. SL2023A04J00179, 2024A04J3312), and Guangzhou Clinical Specialty Program (No. 2023C-TS01).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Accordance statement

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yimin Li and Xiaoqing Liu have contributed equally to the study.
==== Refs
References

1. Fernández S Grafia I Peyrony O Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study Crit Care 2024 28 1 243 10.1186/s13054-024-05029-4 39014504
Fernández S, Grafia I, Peyrony O, et al. Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study. Crit Care. 2024;28(1):243. 10.1186/s13054-024-05029-4.39014504 10.1186/s13054-024-05029-4
2. Singer M Deutschman CS Seymour CW The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA 2016 315 8 801 810 10.1001/jama.2016.0287 26903338
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10. 10.1001/jama.2016.0287.26903338 10.1001/jama.2016.0287
3. Liu V Escobar GJ Greene JD Hospital deaths in patients with sepsis from 2 independent cohorts JAMA 2014 312 1 90 92 10.1001/jama.2014.5804 24838355
Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312(1):90–2. 10.1001/jama.2014.5804.24838355 10.1001/jama.2014.5804
4. Mayr FB Yende S Angus DC Epidemiology of severe sepsis Virulence 2014 5 1 4 11 10.4161/viru.27372 24335434
Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11. 10.4161/viru.27372.24335434 10.4161/viru.27372
5. Hotchkiss RS Moldawer LL Opal SM Sepsis and septic shock Nat Rev Dis Primers 2016 2 16045 10.1038/nrdp.2016.45 28117397
Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. 10.1038/nrdp.2016.45.28117397 10.1038/nrdp.2016.45
6. Hotchkiss RS Monneret G Payen D Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy Nat Rev Immunol 2013 13 12 862 874 10.1038/nri3552 24232462
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–74. 10.1038/nri3552.24232462 10.1038/nri3552
7. Skirecki T Drechsler S Jeznach A An early myelosuppression in the acute mouse sepsis is partly outcome-dependent Front Immunol 2021 12 708670 10.3389/fimmu.2021.708670 34367170
Skirecki T, Drechsler S, Jeznach A, et al. An early myelosuppression in the acute mouse sepsis is partly outcome-dependent. Front Immunol. 2021;12:708670. 10.3389/fimmu.2021.708670.34367170 10.3389/fimmu.2021.708670
8. Ong DSY Chong GM Chemaly RF Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression Clin Microbiol Infect 2022 28 10 1335 1344 10.1016/j.cmi.2022.05.034 35709902
Ong DSY, Chong GM, Chemaly RF, et al. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect. 2022;28(10):1335–44. 10.1016/j.cmi.2022.05.034.35709902 10.1016/j.cmi.2022.05.034
9. Zhang Z Li R Chen Y Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study BMC Infect Dis 2022 22 1 788 10.1186/s12879-022-07747-y 36241980
Zhang Z, Li R, Chen Y, et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study. BMC Infect Dis. 2022;22(1):788. 10.1186/s12879-022-07747-y.36241980 10.1186/s12879-022-07747-y
10. Zhang Z Liu X Sang L Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study BMC Infect Dis 2021 21 1 1026 10.1186/s12879-021-06698-0 34592936
Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study. BMC Infect Dis. 2021;21(1):1026. 10.1186/s12879-021-06698-0.34592936 10.1186/s12879-021-06698-0
11. Marandu T Dombek M Cook CH Impact of cytomegalovirus load on host response to sepsis Med Microbiol Immunol 2019 208 3–4 295 303 10.1007/s00430-019-00603-y 30976913
Marandu T, Dombek M, Cook CH. Impact of cytomegalovirus load on host response to sepsis. Med Microbiol Immunol. 2019;208(3–4):295–303. 10.1007/s00430-019-00603-y.30976913 10.1007/s00430-019-00603-y
12. Unterberg M Ehrentraut SF Bracht T Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis Crit Care 2023 27 1 417 10.1186/s13054-023-04713-1 37907989
Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27(1):417. 10.1186/s13054-023-04713-1.37907989 10.1186/s13054-023-04713-1
13. Cowley NJ Owen A Shiels SC Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial JAMA Intern Med 2017 177 6 774 783 10.1001/jamainternmed.2017.0895 28437539
Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017;177(6):774–83. 10.1001/jamainternmed.2017.0895.28437539 10.1001/jamainternmed.2017.0895
14. Razonable RR Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients Clin Microbiol Infect 2023 29 9 1144 1149 10.1016/j.cmi.2023.03.020 36963566
Razonable RR. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. Clin Microbiol Infect. 2023;29(9):1144–9. 10.1016/j.cmi.2023.03.020.36963566 10.1016/j.cmi.2023.03.020
15. Griffiths P Reeves M Pathogenesis of human cytomegalovirus in the immunocompromised host Nat Rev Microbiol 2021 19 12 759 773 10.1038/s41579-021-00582-z 34168328
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759–73.34168328 10.1038/s41579-021-00582-z
